11 investors predict a colorful, if difficult, future for psychedelic startups
TechCrunch
MAY 12, 2023
In the meantime, pharma and big biotech VC firms are more interested in exploring the non-hallucinogenic psychedelic pathways. Big pharma awaits more data on this front before an M&A move.
Let's personalize your content